PRESS RELEASE
The Board of Directors of Active Biotech AB (publ) has issued a
notice to the Annual General Meeting, which is to take place on
Thursday, May 23, 2019, at 5 pm at the company's offices,
Scheelevägen 22 in Lund, Sweden.
Please see the attached notification, which is
being announced within short in Svenska Dagbladet and Post- och
Inrikes Tidningar.
Lund, 24 April 2019
ACTIVE BIOTECH AB (PUBL)
THE BOARD OF DIRECTORS
Active Biotech AB
(publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with
focus on neurodegenerative/inflammatory diseases and cancer.
Laquinimod, an orally administered small molecule with unique
immunomodulatory properties in development for neurodegenerative
diseases. ANYARA (naptumumab), an immunotherapy, in development for
cancer indications in partnership with NeoTX Therapeutics Ltd.
Furthermore, commercial activities are conducted for the
tasquinimod, paquinimod and SILC projects. Please visit
www.activebiotech.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
NOTICE OF ANNUAL GENERAL MEETING
OF SHAREHOLDERS
The shareholders of Active Biotech AB (publ) are invited to the Annual
General Meeting of shareholders to be held on Thursday, May 23,
2019, at 5 p.m. in the company's offices, Scheelevägen 22 in Lund,
Sweden.
ENTITLEMENT TO
PARTICIPATE
Shareholders who wish to participate in the Meeting must (i) be
recorded in the register of shareholders maintained by Euroclear
Sweden AB on Friday, May 17, 2019, and (ii) notify the Company of
their intention to participate in the Meeting not later than on
Friday, May 17, 2019.
Shareholders who have trustee-registered
their shares must re-register the shares in their own name to be
entitled to participate in the Meeting. Such registration, which
may be temporary, must be completed on Friday, May 17, 2019.
Accordingly, shareholders must inform the trustee of this request
in ample time prior to this date.
There are a total of 145,236,480 shares and votes in Active
Biotech. The Company holds no treasury shares.
NOTICE OF
PARTICIPATION
Notice of participation in the Meeting can be made in writing to
Active Biotech AB (publ), Attn: Susanne Jönsson, P.O. Box 724,
SE-220 07 Lund, Sweden, by telephone +46 (0)46-19 20 00 or by
e-mail to susanne.jonsson@activebiotech.com. The notice shall
include name, personal/corporate identity number, number of shares
held, daytime telephone number and, if applicable, the number of
advisors (not more than two) that will accompany the shareholder at
the Meeting.
Shareholders represented by proxy shall issue a dated and signed
power of attorney for the proxy. If the power of attorney is issued
on behalf of a legal entity, a certified copy of a registration
certificate or corresponding document indicating the authorized
signatories of the legal entity shall be appended. The original
power of attorney and, where applicable, the certificate should be
submitted to the Company at the address indicated above well in
advance of the Meeting. Proxy forms are provided at the Company's
website, www.activebiotech.com, and sent to shareholders that so
request.
PROPOSED
AGENDA
-
Opening of the Meeting
-
Election of Chairman of the
Meeting
-
Preparation and approval of the voting
list
-
Election of one or two persons to
verify the minutes
-
Approval of the agenda for the
Meeting
-
Determination of whether the Meeting
has been duly convened
-
Presentation of the Annual Report and
the Auditors' Report, and the Consolidated Accounts and the
Auditors' Report for the Group
-
CEO's account of operations
-
Resolution concerning the adoption of
the Income Statement and the Balance Sheet, and the Consolidated
Income Statement and the Consolidated Balance Sheet
-
Resolution concerning the disposition
of the Company's results pursuant to the adopted Balance
Sheet
-
Resolution on discharge from liability
of the members of the Board of Directors and the CEO
-
Determination of the number of members
and deputy members of the Board of Directors and the number of
auditors and deputy auditors
-
Determination of fees payable to the
Board of Directors and auditor
-
Election of the Board of Directors,
Chairman of the Board and auditor
-
Resolution concerning Election
Committee
-
The Board of Director's proposal
regarding guidelines for remuneration of senior executives
-
The Board of Director's proposal
regarding amendment of the Articles of Association
-
The Board of Director's proposal
regarding share issue authorization
-
Closing of the Meeting
PROPOSED
RESOLUTIONS
Disposition of the Company's results (item
10)
The Board proposes that no dividend is paid and that the Company's
accumulated loss shall be carried forward.
Board of
Directors, etc. (items 2 and 12 - 15)
The Election Committee's proposed resolutions regarding these
matters will be announced in a separate press release as soon as
possible.
Guidelines for
remuneration of senior executives (item 16)
The Board proposes guidelines principally entailing that the
Company shall offer total remuneration on market terms,
facilitating the recruitment and retention of competent senior
executives. Remuneration of senior executives may comprise fixed
salary, any variable salary, pension and other benefits. The fixed
salary shall take into consideration the individual's area of
responsibility and experience. The variable salary shall, where
applicable, depend on the individual's fulfilment of quantitative
and qualitative goals. Pension benefits shall comprise defined
contribution schemes. For senior executives covered by the ITP
plan, pension premiums shall correspond to the stipulations in the
ITP plan. For other senior executives, pension premiums shall not
exceed 25 percent of the fixed salary. The guidelines correspond to
the principles applied to date.
Amendment of the
articles of association (item 17)
The Board proposes that the Meeting resolves to amend the Articles
of Association so that (i) the object of the Company's operations
(§ 3) shall read "The company shall engage,
directly or through subsidiaries, in research, development,
production, marketing and sales of medical, chemical and
biotechnology products, conduct administrative services for the
group and undertake any other operations compatible therewith",
(ii) the limits for the number of shares in the Company (§ 5) are
raised from 40,000,000 - 160,000,000 shares to 100,000,000 -
400,000,000 shares and (iii) the Company's name shall be Active
Biotech AB (publ).
Share issue
authorization (item 18)
The Board proposes that the Meeting resolves to grant authorization
to the Board, for a period that does not extend past the date of
the next Annual General Meeting, on one or several occasions, with
or without pre-emptive rights for the shareholders, to resolve on
the issue of new shares and/or convertibles. It shall also be
possible to make such an issue resolution stipulating in-kind
payment, the right to offset debt or other conditions. The number
of shares issued, or which may arise through the conversion of
convertibles issued with the support of the authorization, may
correspond to not more than 30 per cent of the total number of
shares in the Company after utilization of the authorization. The
purpose of the authorization is to enable the financing,
commercialization and development of the Company's projects and to
provide flexibility in commercial negotiations relating to
partnerships.
___________________
DOCUMENTATION,
ETC.
The Annual Report and other supporting resolution documentation
will be held available at the Company's premises at Scheelevägen 22
in Lund, Sweden, and on the Company's website,
www.activebiotech.com, not later than three weeks prior to the
Meeting. The documents will be sent to shareholders who request a
copy and specify their postal address. Shareholders are reminded of
their right to request information under Chapter 7, Section 32 of
the Swedish Companies Act.
For information about the processing of your
personal data, please refer to
https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.
Active Biotech's corporate registration number is 556223-9227 and
its registered office is in Lund, Sweden.
Lund, April 2019
The Board of Directors of Active Biotech AB
(publ)
Active Biotech: NOTICE OF ANNUAL
GENERAL MEETING OF SHAREHOLDERS
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024